Michael J Keating

Michael J Keating

UNVERIFIED PROFILE

Are you Michael J Keating?   Register this Author

Register author
Michael J Keating

Michael J Keating

Publications by authors named "Michael J Keating"

Are you Michael J Keating?   Register this Author

100Publications

3381Reads

24Profile Views

Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?

Acta Haematol 2018 16;140(1):51-54. Epub 2018 Aug 16.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491382DOI Listing
June 2019

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.

Leuk Lymphoma 2019 Jun 4:1-4. Epub 2019 Jun 4.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1622098DOI Listing
June 2019

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Oncotarget 2019 Apr 19;10(29):2793-2809. Epub 2019 Apr 19.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497463PMC
April 2019

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.

Leuk Lymphoma 2018 11 21;59(11):2686-2691. Epub 2018 Feb 21.

a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1439167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135679PMC
November 2018

Toward the potential cure of leukemias in the next decade.

Cancer 2018 11 6;124(22):4301-4313. Epub 2018 Oct 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31669
Publisher Site
http://dx.doi.org/10.1002/cncr.31669DOI Listing
November 2018

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.

Oncotarget 2018 Sep 14;9(72):33710-33718. Epub 2018 Sep 14.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154750PMC
September 2018

Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.

Leuk Lymphoma 2018 06 3;59(6):1427-1438. Epub 2017 Oct 3.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1376747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882591PMC
June 2018

Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.

Oncotarget 2018 May 18;9(38):24980-24991. Epub 2018 May 18.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/25166
Publisher Site
http://dx.doi.org/10.18632/oncotarget.25166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982765PMC
May 2018

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.

Oncotarget 2018 Apr 20;9(30):21268-21280. Epub 2018 Apr 20.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940394PMC
April 2018

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

Br J Haematol 2018 02 21;180(4):597-600. Epub 2016 Oct 21.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14398DOI Listing
February 2018

B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.

Mol Cancer Res 2017 12 23;15(12):1692-1703. Epub 2017 Aug 23.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-17-0026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714317PMC
December 2017

Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.

Br J Haematol 2017 10 24;179(2):266-271. Epub 2017 Jul 24.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638689PMC
October 2017

The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.

Neoplasia 2017 Oct 30;19(10):762-771. Epub 2017 Aug 30.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, 1515 Holcombe Blvd., Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.07.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577399PMC
October 2017

Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.

Expert Opin Pharmacother 2017 Jun 16;18(9):857-873. Epub 2017 May 16.

a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1324420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488229PMC
June 2017

Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections.

EBioMedicine 2017 Jun 19;20:182-192. Epub 2017 Apr 19.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2017.04.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478184PMC
June 2017

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.

Oncotarget 2017 Mar;8(10):16259-16274

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369961PMC
March 2017

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Leuk Lymphoma 2016 16;57(6):1494-7. Epub 2015 Nov 16.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1102243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963009PMC
January 2017

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

J Clin Oncol 2017 Jan 21;35(2):166-174. Epub 2016 Nov 21.

Qiushi Chen and Turgay Ayer, Georgia Institute of Technology; Christopher R. Flowers, Emory University, Atlanta, GA; Qiushi Chen and Jagpreet Chhatwal, Massachusetts General Hospital; Jagpreet Chhatwal, Harvard Medical School, Boston, MA; Nitin Jain, William G. Wierda, Michael J. Keating, and Hagop M. Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, TX; and Susan M. O'Brien, University of California Irvine Medical Center, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2856DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559889PMC
January 2017

Metabolism pathways in chronic lymphocytic leukemia.

Leuk Lymphoma 2016 8;57(4):758-65. Epub 2015 Dec 8.

e Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1106533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794359PMC
December 2016

Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53.

Mitochondrion 2016 Nov 17;31:33-39. Epub 2016 Sep 17.

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mito.2016.09.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108679PMC
November 2016

Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.

Oncotarget 2016 Nov;7(44):71378-71389

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.12110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342085PMC
November 2016

Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Expert Opin Drug Metab Toxicol 2016 Nov 11;12(11):1381-1392. Epub 2016 Oct 11.

a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2016.1239717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391303PMC
November 2016

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Br J Haematol 2016 Nov 9;175(3):462-466. Epub 2016 Sep 9.

Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14324DOI Listing
November 2016

Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.

Clin Cancer Res 2016 Sep 29;22(18):4712-26. Epub 2016 Mar 29.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118040PMC
September 2016

Richter transformation of CLL.

Expert Rev Hematol 2016 Aug 28;9(8):793-801. Epub 2016 Jun 28.

a Department of Leukemia , MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2016.1199948DOI Listing
August 2016

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome.

J Vis Exp 2016 06 15(112). Epub 2016 Jun 15.

Department of Leukemia, The University of Texas MD Anderson Cancer Center;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/53300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927797PMC
June 2016

Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.

Oncotarget 2016 Jun;7(26):39458-39472

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129945PMC
June 2016

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.

Leuk Lymphoma 2016 May 19;57(5):1054-9. Epub 2015 Oct 19.

a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1092527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837105PMC
May 2016

Ibrutinib for Chronic Lymphocytic Leukemia.

N Engl J Med 2016 04;374(16):1592-3

University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1600328DOI Listing
April 2016

Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells.

Leuk Lymphoma 2016 Feb 28;57(2):436-444. Epub 2015 Sep 28.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1063141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814351PMC
February 2016

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

Cancer 2015 Nov 28;121(21):3869-76. Epub 2015 Jul 28.

Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824541PMC
November 2015

Shifting paradigms in the treatment of chronic lymphocytic leukemia.

Future Oncol 2015 ;11(4):641-57

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.288DOI Listing
October 2015

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Clin Cancer Res 2015 Aug 31;21(16):3705-15. Epub 2015 Mar 31.

Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas. Department of Leukemia, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537801PMC
August 2015

Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.

Mod Pathol 2015 Aug 8;28(8):1130-7. Epub 2015 May 8.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2015.58DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522203PMC
August 2015

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.

Br J Haematol 2015 Jul 18;170(1):125-8. Epub 2014 Dec 18.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13269DOI Listing
July 2015

Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Clin Lymphoma Myeloma Leuk 2015 Jul 11;15(7):420-7. Epub 2015 Feb 11.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874253PMC
July 2015

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Clin Lymphoma Myeloma Leuk 2015 Jul 19;15(7):385-91. Epub 2015 Feb 19.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905707PMC
July 2015

Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.

Blood 2015 Feb 23;125(7):1126-36. Epub 2014 Dec 23.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX; and Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2014-01-54
Publisher Site
http://dx.doi.org/10.1182/blood-2014-01-546796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326772PMC
February 2015

Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.

Blood 2015 Jan;125(2):407-10

Departments of Experimental Therapeutics and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-585364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287645PMC
January 2015

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

Blood 2014 Dec;124(25):3829-30

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-10-604272DOI Listing
December 2014

SnapShot: chronic lymphocytic leukemia.

Cancer Cell 2014 Nov 10;26(5):770-770.e1. Epub 2014 Nov 10.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.10.020DOI Listing
November 2014

The proceedings of the initial meeting of the Society of Hematologic Oncology 2013.

Clin Lymphoma Myeloma Leuk 2014 Sep;14 Suppl:S1

Professor of Medicine & Internist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Co-Founder & Director, Society of Hematologic Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.08.001DOI Listing
September 2014

Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL.

Blood 2014 Aug;124(7):1192-5

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-04-565754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133491PMC
August 2014